Alnylam Pharmaceuticals, Inc. (LON:0HD2)

Alnylam Pharmaceuticals Ratios and Metrics

Market cap in millions GBP. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Nov 6, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	44,422	24,243	18,858	24,266	14,979	11,060
Market Cap Growth	51.86%	28.56%	-22.29%	62.00%	35.43%	14.08%
Enterprise Value	44,459	24,200	19,060	24,537	14,677	10,722
Last Close Price	330.82	190.55	151.59	191.34	119.22	99.03
PS Ratio	18.60	13.50	13.14	28.18	24.02	30.64
PB Ratio	255.29	452.40	-108.87	-184.79	34.48	14.86
P/TBV Ratio	255.29	452.40	-	-	34.48	14.86
P/FCF Ratio	269.74	-	572.67	-	-	-
P/OCF Ratio	224.60	-	230.62	-	-	-
EV/Sales Ratio	18.23	13.48	13.28	28.50	23.54	29.70
EV/FCF Ratio	269.97	-	578.81	-	-	-
Debt / Equity Ratio	11.86	40.89	-12.16	-16.51	3.72	1.57
Debt / FCF Ratio	12.53	-	63.96	-	-	-
Asset Turnover	0.71	0.56	0.50	0.29	0.24	0.17
Inventory Turnover	6.83	3.86	2.85	1.57	1.74	1.19
Quick Ratio	2.37	2.61	2.86	3.17	3.79	4.23
Current Ratio	2.54	2.78	3.08	3.51	4.04	4.47
Return on Equity (ROE)	32.73%	-	-	-526.14%	-106.31%	-69.92%
Return on Assets (ROA)	3.65%	-2.74%	-4.78%	-13.65%	-12.56%	-17.85%
Return on Capital (ROIC)	5.74%	-4.19%	-7.17%	-18.77%	-16.46%	-23.80%
Earnings Yield	0.07%	-0.92%	-1.83%	-3.87%	-4.21%	-5.68%
FCF Yield	0.37%	-0.14%	0.18%	-2.10%	-3.54%	-4.54%
Buyback Yield / Dilution	-4.82%	-2.20%	-2.64%	-2.73%	-3.01%	-5.24%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.